Outpacing infectious diseases: African swine fever virus vaccine development

Lead Research Organisation: The Pirbright Institute
Department Name: UNLISTED


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.


10 25 50
Description This project is a partnering award with Prof Bert Jacobs and Dr kathy Sykes, Biodeisgn Institute, Arizona State University. to utse high throughput methods they have developed for cloning and expressing antigens in plasmids and recombinant vaccinia viruses. Using these methods all the genes coded by a strain of ASFV circulating in the caucasus and Russian Federation have been cloned in DNA plasmids and 47 in recombinant vaccinia viruses. A protocol was optimised to immunise pigs with pools of DNA plasmids and boost with recombinant vaccinia viruses. Immune responses to individual antigens was measured using a library of recombinant ASFV antigens. The first results from an immunisation and challenge experiment in pigs indicated that delivery of the 47 antigens reduced the levels of virus in blood and some tissues incluidng spleen. Thus the data suggest that some protective effect was achieved. Further funding was obtained and this has lead identification of 4 novel ASFV antigens that in combination with 4 other ASFV antigens can induce 100% protection in pigs against challenge with virulent virus. A patent application has been filed and the results have been published in J Virol, a high impact Virology journal.

The project has provided funds to faciltate the collaboration by enabling joint meetings to be conducted.
Exploitation Route Potentially protective African swine fever virus antigens have been identified which will be incorporated into vaccine discovery programmes. methods have been developed to deliver pools of DNA plasmids and recombinant vaccinia viruses to pigs. These will be useful for studies with other pig diseases.
Sectors Agriculture, Food and Drink,Education,Pharmaceuticals and Medical Biotechnology

Description The work has identified potentially protective African swine fever virus antigens which in future may be incorporated into effective vaccines. No vaccine is currently available. The genes encoding these antigens have been cloned into DNA plasmids and recombinant vaccinia virus vectors. A method for delivery of genes to pigs by DNA prime and recombinant vaccinia virus boost has been optimized and will be useful for study of immune responses and design of vaccines for other pig diseases. The immunogenic and potentially protective antigens have been filed as a patent application. The work was continued in projects funded by DEFRA.
First Year Of Impact 2017
Sector Agriculture, Food and Drink,Education,Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic

Description Collaboration with Arizona State University ASFV vaccine development 
Organisation Arizona State University
Country United States 
Sector Academic/University 
PI Contribution Immunisation and challenge of pigs with ASFV. Expertise on ASFV
Collaborator Contribution Reagents for immunisation of pigs. Expertise on viral vectored vaccines and DNA vaccines
Impact Patent Application and Publication in progress
Start Year 2010
Description Outpacing Infectious Diseases Collaboration 
Organisation Arizona State University
Department Biodesign Institute
Country United States 
Sector Academic/University 
PI Contribution We carried out testing of candidate vaccines for African swine fever virus prepared by Arizona State University
Collaborator Contribution Reagents for vaccination experiments were prepared by our collaborators
Impact The results have led to further funding DEFRA SE1514, SE1515 . BBSRC CIDLID project BB/H008969/1 2010 -2014 An invention disclosure has been filed and patent application is in progress. The project involves molecular biology, virology, immunology, pathogenesis
Start Year 2012